Showing results (181-190 of 255) with videos related to
Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumorsJ-C Soria, J Cortes, C Massard, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?S Postel-Vinay, Y Boursin, C Massard, et al.Cell Death & Disease|September 19, 2014
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancerY Loriot, P Mordant, D Dugue, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2013
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancerB Besse, R S Heist, V A Papadmitrakopoulou, et al.British Journal of Cancer|August 11, 2011
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasF Farace, C Massard, N Vimond, et al.Revue Des Maladies Respiratoires|February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]D Moro-Sibilot, F Barlesi, J F Timsit, et al.ESMO Open|March 5, 2023
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancerC M Rudin, A Cervantes, A Dowlati, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancerC Massard, A Azaro, J-C Soria, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2011
Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinomaP Hofman, M Ilie, V Hofman, et al.Pageof 26